Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

The ubiquitin-like modifier FAT10 interferes with SUMO activation.

Aichem A, Sailer C, Ryu S, Catone N, Stankovic-Valentin N, Schmidtke G, Melchior F, Stengel F, Groettrup M.

Nat Commun. 2019 Oct 1;10(1):4452. doi: 10.1038/s41467-019-12430-z.

2.

Solar autocalibrating XUV-IR spectrometer system (SOLACER) for the measurement of solar spectral irradiance.

Schmidtke G, Finsterle W, van Ruymbeke M, Haberreiter M, Schäfer R, Zhu P, Brunner R.

Appl Opt. 2019 Aug 1;58(22):6182-6192. doi: 10.1364/AO.58.006182.

PMID:
31503944
3.

Analysis of modification and proteolytic targeting by the ubiquitin-like modifier FAT10.

Aichem A, Boehm AN, Catone N, Schmidtke G, Groettrup M.

Methods Enzymol. 2019;618:229-256. doi: 10.1016/bs.mie.2018.12.040. Epub 2019 Feb 8.

PMID:
30850054
4.

Author Correction: The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation.

Aichem A, Anders S, Catone N, Rößler P, Stotz S, Berg A, Schwab R, Scheuermann S, Bialas J, Schütz-Stoffregen MC, Schmidtke G, Peter C, Groettrup M, Wiesner S.

Nat Commun. 2018 Nov 2;9(1):4646. doi: 10.1038/s41467-018-07183-0.

5.

Experiences with a three-current ionization chamber as primary detector standard for absolute calibration in space.

Schaefer R, Schmidtke G, Brunner R.

Appl Opt. 2018 Aug 20;57(24):6851-6859. doi: 10.1364/AO.57.006851.

PMID:
30129569
6.

The structure of the ubiquitin-like modifier FAT10 reveals an alternative targeting mechanism for proteasomal degradation.

Aichem A, Anders S, Catone N, Rößler P, Stotz S, Berg A, Schwab R, Scheuermann S, Bialas J, Schütz-Stoffregen MC, Schmidtke G, Peter C, Groettrup M, Wiesner S.

Nat Commun. 2018 Aug 20;9(1):3321. doi: 10.1038/s41467-018-05776-3. Erratum in: Nat Commun. 2018 Nov 2;9(1):4646.

7.

The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28αβ and equally degrade FAT10.

Schmidtke G, Schregle R, Alvarez G, Huber EM, Groettrup M.

Mol Immunol. 2019 Sep;113:22-30. doi: 10.1016/j.molimm.2017.11.030. Epub 2017 Dec 6.

PMID:
29208314
8.

Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins.

Nathan JA, Spinnenhirn V, Schmidtke G, Basler M, Groettrup M, Goldberg AL.

Cell. 2013 Feb 28;152(5):1184-94. doi: 10.1016/j.cell.2013.01.037.

9.

FAT10ylation as a signal for proteasomal degradation.

Schmidtke G, Aichem A, Groettrup M.

Biochim Biophys Acta. 2014 Jan;1843(1):97-102. doi: 10.1016/j.bbamcr.2013.01.009. Epub 2013 Jan 18. Review.

10.

NUB1 modulation of GSK3β reduces tau aggregation.

Richet E, Pooler AM, Rodriguez T, Novoselov SS, Schmidtke G, Groettrup M, Hanger DP, Cheetham ME, van der Spuy J.

Hum Mol Genet. 2012 Dec 15;21(24):5254-67. doi: 10.1093/hmg/dds376. Epub 2012 Sep 10.

PMID:
22965877
11.

FAT10 and NUB1L bind to the VWA domain of Rpn10 and Rpn1 to enable proteasome-mediated proteolysis.

Rani N, Aichem A, Schmidtke G, Kreft SG, Groettrup M.

Nat Commun. 2012 Mar 20;3:749. doi: 10.1038/ncomms1752.

PMID:
22434192
12.

The inherited blindness protein AIPL1 regulates the ubiquitin-like FAT10 pathway.

Bett JS, Kanuga N, Richet E, Schmidtke G, Groettrup M, Cheetham ME, van der Spuy J.

PLoS One. 2012;7(2):e30866. doi: 10.1371/journal.pone.0030866. Epub 2012 Feb 7.

13.

USE1 is a bispecific conjugating enzyme for ubiquitin and FAT10, which FAT10ylates itself in cis.

Aichem A, Pelzer C, Lukasiak S, Kalveram B, Sheppard PW, Rani N, Schmidtke G, Groettrup M.

Nat Commun. 2010 May 4;1:13. doi: 10.1038/ncomms1012.

PMID:
20975683
14.

Degradation of FAT10 by the 26S proteasome is independent of ubiquitylation but relies on NUB1L.

Schmidtke G, Kalveram B, Groettrup M.

FEBS Lett. 2009 Feb 4;583(3):591-4. doi: 10.1016/j.febslet.2009.01.006. Epub 2009 Jan 21.

15.

The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition.

Kalveram B, Schmidtke G, Groettrup M.

J Cell Sci. 2008 Dec 15;121(Pt 24):4079-88. doi: 10.1242/jcs.035006. Epub 2008 Nov 25.

16.
17.

Identification of homozygous transgenic mice by genomic real-time PCR.

Schmidtke G, Groettrup M.

Methods Mol Biol. 2008;429:45-58. doi: 10.1007/978-1-60327-040-3_4.

PMID:
18695958
18.

Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon.

Lukasiak S, Schiller C, Oehlschlaeger P, Schmidtke G, Krause P, Legler DF, Autschbach F, Schirmacher P, Breuhahn K, Groettrup M.

Oncogene. 2008 Oct 9;27(46):6068-74. doi: 10.1038/onc.2008.201. Epub 2008 Jun 23.

PMID:
18574467
19.

Activating the ubiquitin family: UBA6 challenges the field.

Groettrup M, Pelzer C, Schmidtke G, Hofmann K.

Trends Biochem Sci. 2008 May;33(5):230-7. doi: 10.1016/j.tibs.2008.01.005. Epub 2008 Mar 18. Review.

PMID:
18353650
20.

UBE1L2, a novel E1 enzyme specific for ubiquitin.

Pelzer C, Kassner I, Matentzoglu K, Singh RK, Wollscheid HP, Scheffner M, Schmidtke G, Groettrup M.

J Biol Chem. 2007 Aug 10;282(32):23010-4. Epub 2007 Jun 19.

21.

The UBA domains of NUB1L are required for binding but not for accelerated degradation of the ubiquitin-like modifier FAT10.

Schmidtke G, Kalveram B, Weber E, Bochtler P, Lukasiak S, Hipp MS, Groettrup M.

J Biol Chem. 2006 Jul 21;281(29):20045-54. Epub 2006 May 17.

22.

Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells.

Waeckerle-Men Y, Allmen EU, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HP, Groettrup M.

Vaccine. 2006 Mar 10;24(11):1847-57. Epub 2005 Oct 25.

PMID:
16288821
23.

FAT10, a ubiquitin-independent signal for proteasomal degradation.

Hipp MS, Kalveram B, Raasi S, Groettrup M, Schmidtke G.

Mol Cell Biol. 2005 May;25(9):3483-91.

24.

NEDD8 ultimate buster-1L interacts with the ubiquitin-like protein FAT10 and accelerates its degradation.

Hipp MS, Raasi S, Groettrup M, Schmidtke G.

J Biol Chem. 2004 Apr 16;279(16):16503-10. Epub 2004 Feb 2.

25.

Structural plasticity of the proteasome and its function in antigen processing.

Groettrup M, van den Broek M, Schwarz K, Macagno A, Khan S, de Giuli R, Schmidtke G.

Crit Rev Immunol. 2001;21(4):339-58. Review.

PMID:
11922078
26.

Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein.

Khan S, de Giuli R, Schmidtke G, Bruns M, Buchmeier M, van den Broek M, Groettrup M.

J Immunol. 2001 Nov 1;167(9):4801-4.

27.

The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis.

Raasi S, Schmidtke G, Groettrup M.

J Biol Chem. 2001 Sep 21;276(38):35334-43. Epub 2001 Jul 9.

28.

Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro.

Moradpour D, Grabscheid B, Kammer AR, Schmidtke G, Groettrup M, Blum HE, Cerny A.

Hepatology. 2001 May;33(5):1282-7.

PMID:
11343257
29.

Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why?

Groettrup M, Khan S, Schwarz K, Schmidtke G.

Biochimie. 2001 Mar-Apr;83(3-4):367-72. Review.

PMID:
11295499
30.

Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope.

Schwarz K, van Den Broek M, Kostka S, Kraft R, Soza A, Schmidtke G, Kloetzel PM, Groettrup M.

J Immunol. 2000 Jul 15;165(2):768-78.

31.

The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Schwarz K, de Giuli R, Schmidtke G, Kostka S, van den Broek M, Kim KB, Crews CM, Kraft R, Groettrup M.

J Immunol. 2000 Jun 15;164(12):6147-57.

32.

Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome.

Schmidtke G, Emch S, Groettrup M, Holzhutter HG.

J Biol Chem. 2000 Jul 21;275(29):22056-63.

33.

A ubiquitin-like protein which is synergistically inducible by interferon-gamma and tumor necrosis factor-alpha.

Raasi S, Schmidtke G, de Giuli R, Groettrup M.

Eur J Immunol. 1999 Dec;29(12):4030-6.

34.

[Intracellular processing of viral and tumor antigens by proteasomes].

Groettrup M, Schmidtke G.

Schweiz Med Wochenschr. 1999 Nov 6;129(44):1660-5. Review. German.

PMID:
10588025
35.

How an inhibitor of the HIV-I protease modulates proteasome activity.

Schmidtke G, Holzhütter HG, Bogyo M, Kairies N, Groll M, de Giuli R, Emch S, Groettrup M.

J Biol Chem. 1999 Dec 10;274(50):35734-40.

36.

Characterization of neutralizing anti-pre-S1 and anti-pre-S2 (HBV) monoclonal antibodies and their fragments.

Küttner G, Kramer A, Schmidtke G, Giessmann E, Dong L, Roggenbuck D, Scholz C, Seifert M, Stigler RD, Schneider-Mergener J, Porstmann T, Höhne W.

Mol Immunol. 1999 Jul;36(10):669-83.

PMID:
10509818
38.

Selective proteasome inhibitors: modulators of antigen presentation?

Groettrup M, Schmidtke G.

Drug Discov Today. 1999 Feb;4(2):63-71.

PMID:
10234158
39.
40.
41.

Structure and structure formation of the 20S proteasome.

Schmidt M, Schmidtke G, Kloetzel PM.

Mol Biol Rep. 1997 Mar;24(1-2):103-12. Review.

PMID:
9228290
42.

Analysis of mammalian 20S proteasome biogenesis: the maturation of beta-subunits is an ordered two-step mechanism involving autocatalysis.

Schmidtke G, Kraft R, Kostka S, Henklein P, Frömmel C, Löwe J, Huber R, Kloetzel PM, Schmidt M.

EMBO J. 1996 Dec 16;15(24):6887-98.

43.

Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus.

Feist E, Dörner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, Burmester GR, Kloetzel PM.

J Exp Med. 1996 Oct 1;184(4):1313-8.

44.

[Quality control of flow cytometry by means of fluorescent particles ("beads")].

Höffkes HG, Schmidtke G.

Infusionsther Transfusionsmed. 1996 Apr;23(2):115-6. German. No abstract available.

PMID:
8777361
45.

Lymphocyte gating of peripheral blood in patients with leukemic low-grade non-Hodgkin's lymphoma by multiparametric flow cytometry.

Höffkes HG, Schmidtke G, Schmucker U, Brittinger G.

Eur J Med Res. 1996 Jan 19;1(4):215-22.

PMID:
9445762
46.

Multiparametric immunophenotyping of B cells in peripheral blood of healthy adults by flow cytometry.

Höffkes HG, Schmidtke G, Uppenkamp M, Schmücker U.

Clin Diagn Lab Immunol. 1996 Jan;3(1):30-6.

47.

Immunophenotyping of B lymphocytes by multiparametric flow cytometry in bone marrow aspirates and peripheral blood of healthy adults.

Höffkes H, Schmidtke G, Schmücker U, Uppenkamp M, Brittinger G.

Eur J Med Res. 1995 Oct 16;1(1):2-8.

PMID:
9392686
48.

Immunophenotyping of B lymphocytes by multiparametric flow cytometry in bone marrow aspirates of healthy adults.

Höffkes HG, Schmidtke G, Schmücker U, Uppenkamp M, Brittinger G.

Ann Hematol. 1995 Sep;71(3):123-8.

PMID:
7548330
49.

Diode laser spectrometer for monitoring up to five atmospheric trace gases in unattended operation.

Schmidtke G, Kohn W, Klocke U, Knothe M, Riedel WJ, Wolf H.

Appl Opt. 1989 Sep 1;28(17):3665-70. doi: 10.1364/AO.28.003665.

PMID:
20555754
50.

Airglow-solar spectrometer instrument (20-700 nm) aboard the San Marco D/L satellite.

Schmidtke G, Seidl P, Wita C.

Appl Opt. 1985 Oct 1;24(19):3206. No abstract available.

PMID:
18224029

Supplemental Content

Loading ...
Support Center